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A B S T R A C T
Insulin resistance has been documented in type 1 diabetes and may contribute to the high risk for cardiovascular dis-
ease in this population and progression of nephropathy. We investigated associations of renal parameters, including uri-
nary albumin excretion rate (UAE), serum creatinine and creatinine clearance, with surrogate measure of insulin sensi-
tivity calculated using a formula derived from euglycemic-hyperinsulinemic clamp studies (estimated glucose disposal
rate, eGDR). Study included 353 patients with type 1 diabetes, none showed signs of adrenal, thyroid, renal, or cardio-
vascular diseases. Insulin sensitivity was measured with eGDR calculated with the equation: 24.31–(12.22´WHR)–
(3.29´HT)–(0.57´HbA1c). The units were mgkg–1min–1; WHR=waist to hip ratio; HT=hypertension. Correlations and
logistic regression analysis were performed to identify relationships between renal parameters and eGDR, individual
components of insulin resistance and risk of insulin resistance. UAE and serum creatinine significantly correlated with
insulin resistance measured by eGDR (r=–0.13, and –0.17, all p<0.05), and its components disorders, WHR and HbA1c.
After stratifying patients in quartiles of eGDR, those in the upper quartile of the eGDR had significantly reduced levels of
UAE and serum creatinine, compared to subjects in lowest quartile. In a logistic regression analysis risk for development
of insulin resistance in our subjects were independently predicted only by UAE (odds ratio=1.01, p<0.01). Our results
provide evidence of associations between insulin resistance and its components disorders with renal parameters, such as
UAE and serum creatinine. Insulin resistance, measured with eGDR, predicts the increment in UAE in subjects with
type 1 diabetes. Since progression to microalbuminuria is likely to occur in majority of diabetic patients, there is a need to
further explore the role of risk factors such as insulin resistance.
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Introduction
Although insulin resistance is usually associated with
the development of type 2 diabetes, it can also be a fea-
ture of patients with type 1 diabetes1,2. Insulin resistance
in subjects with type 1 diabetes may contribute to the
high risk for cardiovascular disease and progression of
nephropathy2,3, because those subjects have elevated blood
pressure, hyperglycemia, dyslipidemia, lowgrade inflam-
mation, endothelial dysfunction, abnormalities in fibri-
nolysis and coagulation4–7. Three large prospective stud-
ies (Pittsburgh Epidemiology of Diabetes Complications,
EURODIAB Prospective Complications Study and Dia-
betes Control and Complications Trial) have shown that
insulin resistance is an independent risk factor for the
micro- (nephropathy, neuropathy and retinopathy) and
macro- (coronary artery disease and peripheral vascular
disease) vascular complications in patients with type 1
diabetes8,9. Prevalence of insulin resistance in type 1 dia-
betes is currently around 20%, and it is continuing to rise
reflecting the rising rates of obesity10–12.
Clinically, insulin resistance in type 1 diabetic pa-
tients is often recognized by their larger requirements
for insulin. However, more recently a validated method
for estimated glucose disposal rate (eGDR), which has
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been previously validated by euglycemic-hyperinsuline-
mic clamp studies, has been developed13. This clinical
score, based on hypertension, waist to hip ratio (WHR)
and hemoglobin A1c (HbA1c), has recently been used in a
number of large epidemiological studies for the non-inva-
sive assessment of insulin sensitivity in patients with
type 1 diabetes10,14–17.
Identification of the determinants of the onset of
early diabetic nephropathy is essential for reducing the
morbidity and mortality associated with diabetes. Many
studies have identified poor glycemic control as the most
important risk factor for progression of diabetic kidney
disease18–20. In addition, blood pressure was also higher
in patients with higher albumin excretion rate compared
to normoalbuminuric patients21. Prior studies have shown
WHR to be a stronger predictor than overall adiposity of
cardiovascular risk factors and complications in type 1
diabetes22,23. All this parameters are included in eGDR,
because the physiological basis of insulin resistance be-
ing related to WHR, hypertension, and glucose intoler-
ance is well founded and described24. Moreover, it was
shown that higher insulin resistance at baseline, esti-
mated by lower level of eGDR, was associated with in-
creased subsequent risk of microvascular complications.
In contrast, insulin dose and the presence of IDF-defined
metabolic syndrome were poor predictors10,17. Based on
this data, it appears that measurement of insulin sensi-
tivity by eGDR can add to the prognostic value of albu-
min excretion in the prediction of subjects at risk of dia-
betic nephropathy.
Insulin resistance precedes and probably contributes
to the development of microalbuminuria and progression
of diabetic kidney disease in type 1 diabetic patients. The
aim of this study, therefore, was to determine the level of
insulin sensitivity in patients with type 1 diabetes using
a surrogate measure of insulin resistance (eGDR), and to
evaluate the associations of renal parameters, including
urinary albumin excretion rate (UAE), serum creatinine
and creatinine clearance with eGDR. We also explored re-
lationship between renal parameters and individual com-
ponents of insulin resistance, and whether disturbances
of renal parameters were associated with progression to
insulin resistance in subjects with type 1 diabetes.
Subjects, Materials and Methods
This study included 353 euthyroid patients with dia-
betes mellitus type 1. Type 1 diabetes was defined as an
onset of diabetes before the age of 35 years and perma-
nent insulin treatment initiated within 1 year of diagno-
sis. Subjects with insulin-treated diabetes secondary to
other pathologies were excluded. The study included pa-
tients following characteristics: age of 18–65 years, mini-
mum duration of type 1 diabetes of 1 year, no medical his-
tory of disorders of thyroid and adrenal gland function,
cardiovascular diseases or electrocardiogram (ECG) evi-
dence of ischemic heart disease, absence of any systemic
disease, and absence of any infections in the previous
month. Patients with chronic renal disease or other
chronic diseases likely to affect renal function were ex-
cluded. Patients were excluded from the study if they had
taken any of the following: lipid-lowering therapy, thy-
roid hormone therapy, medications that might affect glu-
cose metabolism and insulin sensitivity such as gluco-
corticoids, oral contraceptives as well as patients taking
oral glucose-lowering medication. Acute and chronic in-
flammation was excluded on the basis of medical history,
physical examination, and routine laboratory tests, in-
cluding measurement of temperature and urinalysis.
All subjects were studied in the morning after an
overnight fast. Basic anthropometric measurements were
performed on all study subjects. WHR was calculated
from the waist circumference (measured on bare skin as
the narrowest circumference between the 10th rib and
the iliac crest with tailor meter) and hip circumference
(at the widest point of the gluteal muscles) and expressed
in centimeters. Weight was measured by the physician
using a balanced-beam scale with light clothing without
shoes and expressed in kilograms (kg). Height was mea-
sured using a wall mounted stadiometer and expressed in
centimeters (cm). Body mass index (BMI) was calculated
as weight in kilograms divided by the square of height in
meters (kg/m2). Blood pressure was measured twice in
the sitting position with a mercury sphygmomanometer
after a resting period of 10 minutes and expressed in
mmHg. UAE was measured from at least two 24-h urine
samples and determined as the mean of 24-h urine collec-
tions. Patients performed collections on two consecutive
days to minimize variability. Normoalbuminuria was de-
fined as a UAE<30 mg/24h, and microalbuminuria as a
UAE30<300 mg/24h. Those with macroalbuminuria
(UAE300 mg/24h) were excluded from the study. To
measure creatinine clearance, serum and 24-h urine sam-
ples were collected. Creatinine clearance was calculated
from serum and urine creatinine concentrations and
urine volume.
Fasting venous blood samples were collected in the
morning between 08:00 and 09:30 hours after an over-
night fast for the determination of HbA1c (%, reference
range 3.5 to 5.7), high density lipoprotein (HDL) choles-
terol (mmol/L, reference range >1.0 for men, >1.3 for
women), low density (LDL) cholesterol (mmol/L, refer-
ence range <3.0), triglycerides (mmol/L, reference range
<1.7), fasting glucose (mmol/L, reference range 3.0–6.1),
serum creatinine (mmol/L, reference range 79–125), red
blood cell count (RBC) (´1012, reference range 4.34–5.72),
hemoglobin (g/L, reference range 138–175), white blood
cell count (WBC) (´109, reference range 3.4–9.7), and
platelet (´109, reference range 158–424).
Microalbumin and HbA1c were measured spectropho-
tometrically by turbidimetric immuno-inhibition (Olym-
pus AU600, Beckman-Coulter, USA). Results of HbA1c
(%) are expressed in the DCCT-equivalent. Glucose, cho-
lesterol and triglycerides in serum were measured by an
enzymatic colorimetric method. Complete blood count
was determined on an automatic blood counter (Advia
120, Siemens Diagnostic Solutions, USA). Measure of in-
sulin sensitivity (eGDR) is calculated using the equation:
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24.31–12.2´(WHR)–3.29´(AHT)–0.57´(HbA1c), where the
units are mgkg–1min–1, WHR indicates the waist to hip
ratio, AHT indicates blood pressure, and is expressed as:
0-no, 1-yes. Those on blood pressure medications or with
blood pressure >140/90 mmHg were considered to have
hypertension. This equation was derived from a sub-
study of 24 EDC (Epidemiology of Diabetes Complica-
tions) participants (12 men and 12 women drawn from
low, middle and high age-specific tertiles of insulin resis-
tance risk factors in order to represent the spectrum of
insulin resistance) who underwent euglycemic-hyperin-
sulinemic clamp studies13. It should be emphasized that
lower eGDR levels indicate greater insulin resistance.
The study protocol complies with the Declaration of
Helsinki as well as with local institutional guidelines,
and was approved by the local ethics committees.
Differences between groups were examined, depend-
ing on the nature of the data, parametric (t-test) or
nonparametric tests (Mann-Whitney). Correlations be-
tween parameters of renal function with anthropometric
and metabolic variables were determined using Spear-
man rho test. To investigate the relation between renal
parameters with insulin resistance data were also strati-
fied in quartiles of eGDR. Kruskal-Wallis test was used
for calculating the significance of the trend for each vari-
able among the different quartiles. Logistic regression
analysis was used to assess associations of renal parame-
ters with risk of insulin resistance. Level of statistical
significance was chosen to a=0.05. Statistical analysis
was performed by statistical package STATA/IC ver.11.1.
Results
The characteristics of the study subjects are listed in
Table 1. The average age was approximately 38 years,
most were not overweight and 53% of subjects were
male. Mean/median values of BMI, WHR, LDL, HDL
cholesterol, triglycerides, systolic and diastolic blood pre-
ssure, serum creatinine, UAE, and creatinine clearance
were within the normal range for patients with diabetes.
83% of all patients had normoalbuminuria, 17% had
microalbuminuria, and none had macroalbuminuria. Me-
dian of eGDR was 9.68 mgkg–1min–1 (interquartile range
3.9–12.7). There were 178 patients with lower (<9.68
mgkg–1min–1) and 175 with higher (9.68 mgkg–1min–1)
insulin sensitivity. Those with lower insulin sensitivity
were older, had a longer duration of diabetes, as well as
metabolic parameters, except HDL cholesterol concen-
trations that were significantly lower (Table 2). Subjects
with lower insulin sensitivity had significantly elevated
concentrations of serum creatinine and UAE (all p<
0.05), but creatinine clearance concentrations did not
differ between two groups.
Associations of renal parameters with anthropome-
tric and metabolic variables are presented in Table 3. Se-
rum creatinine and UAE were significantly associated
with insulin resistance measured by clinical parameters
(eGDR), with serum creatinine showing the strongest
correlation. In addition, serum creatinine and UAE were
significantly associated with one individual component
of eGDR (WHR and HbA1c). However, as eGDR is a func-
tion of WHR, HbA1c and hypertension, although creati-
nine clearance was in significant correlation with two in-
dividual components of eGDR (WHR and HbA1c), it was
not significantly associated with measure of insulin sen-
sitivity (eGDR). Serum creatinine was also positively cor-
related with duration of diabetes and BMI. Creatinine
clearance significantly correlated with even 6 parame-
ters (age, duration of diabetes, BMI, WHR, HbA1c, and
triglycerides). The magnitude of these associations were
strongest for serum creatinine with WHR (r=0.39, p<
0.001), and creatinine clearance with age (r=–0.26, p<
0.001). UAE significantly correlated only with eGDR and
HbA1c (r=0.13, and 0.13, respectively, all p0.01). Renal
parameters were more modestly associated with serum
lipids and blood pressure, and only creatinine clearance
was significantly correlated with triglycerides. Intercor-
relations among the renal parameters were low and not
significant, for UAE with serum creatinine and creati-
nine clearance (r=0.03, and –0.06, respectively), and for
serum creatinine with creatinine clearance (r=–0.04).
Relationship between renal parameters among those
in the 2nd, 3rd and 4th quartiles of eGDR compared to
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TABLE 1
CLINICAL AND METABOLIC CHARACTERISTICS OF ALL
PATIENTS
Variable X±SD
Interquartile
range
Age (years) 38±11 18–65
Duration of diabetes (years) 16±10 1–48
BMI (kg/m2) 24±3 15–37
WHR 0.82±0.07 0.66–1.07
HbA1c (%) 7.29±1.68 4.4–12.2
SBP (mmHg) 126±15 79–180
DBP (mmHg) 79±9 50–110
Heart rate (beats/min) 74±13 44–111
eGDR (mg/kg–1min–1) 9.31±2.02 3.9–12.7
LDL-cholesterol (mmol/L) 2.8±0.8 0.6–6.2
HDL-cholesterol (mmol/L) 1.7±0.4 0.7–3.6
Triglycerides (mmol/L) 1.1±0.6 0.3–4.0
Serum creatinine (mmol/L) 92±14 52–154
Creatinine clearance (ml/sec) 1.88±0.52 0.93–3.71
UAE (mg/24h) 24.2±32.9 0.9–243.3
RBC (´1012/L) 4.6±0.4 3.2–5.9
Hemoglobin (g/L) 140±15.8 75–179
WBC (´109/L) 6.7±2.1 2.4–13.7
Platelet (´109/L) 259±72 22–549
Smokers/non-smokers 122/231
BMI – body mass index, WHR – waist to hip ratio, SPB – systolic
blood pressure, DBP – diastolic blood pressure, eGDR – estima-
ted glucose disposal rate, UAE – urinary albumin excretion,
RBC – red blood cell count, WBC – white blood cell count
those in quartile 1 are presented in Table 4. Stratifying
renal parameters for degree of insulin sensitivity, deter-
mined according to percentiles of eGDR, trends across
quartiles for serum creatinine and UAE were statisti-
cally significant (all p<0.05). Subjects in the 1st quartile
of eGDR were at significantly elevated UAE and serum
creatinine levels compared to subjects in 2nd, 3rd and 4th
quartiles. The magnitude of these associations were stron-
gest for UAE (p=0.01). Among the different groups no
significant changes in creatinine clearance was found.
In logistic regression analysis, after adjustment for
age, only UAE was significantly associated with risk of
insulin resistance in our subjects (OR=1.01, p=0.009).
Although serum creatinine had strongest correlation with
eGDR (r=–0.17) and especially with individual compo-
nent of eGDR, WHR (r=0.39), these parameter was not
significantly associated with risk of insulin resistance in
our subjects, as well as creatinine clearance.
Discussion
Insulin resistance is the central pathophysiological
phenomenon of metabolic syndrome25, characterized by a
clustering of independent cardiovascular risk factors in-
cluding impaired glucose regulation, central obesity, dy-
slipidemia, and hypertension24. In both, type 1 and type 2
diabetes, the role of insulin resistance seems to be equ-
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TABLE 2
CLINICAL AND METABOLIC CHARACTERISTICS OF PATIENTS DEPENDING ON LEVEL OF INSULIN SENSITIVITY
eGDR<9.68 eGDR9.68 p
Sex (m/f) 115/63 72/103 <0.001
Age (years) 40±11 36±10 <0.001
Duration of diabetes (years) 17±10 14±9 0.01
BMI (kg/m2) 25 (17–37) 24 (15–33) <0.001
Waist circumference (cm) 86 (66–111) 76 (61–102) <0.001
LDL-cholesterol (mmol/L) 3.1±0.9 2.6±0.6 <0.001
HDL-cholesterol (mmol/L) 1.59 (0.8–3.6) 1.76 (0.7–3.6) <0.001
Triglycerides (mmol/L) 1.13 (0.4–5.0) 0.78 (0.3–2.3) <0.001
Fasting glucose (mmol/L) 6.7±2.5 5.8±2.1 0.001
Smokers/non-smokers 72/106 50/125 0.02
Serum creatinine (mmol/L) 93±15 90±12 0.02
UAE (mg/24h) 16.2 (0.9–241) 13.5 (1.4–243) 0.002
Creatinine clearance (ml/sec) 1.88±0.56 1.88±0.48 0.9
BMI – body mass index, eGDR – estimated glucose disposal rate, UAE – urinary albumin excretion
TABLE 3
SPEARMAN CORRELATION ANALYSIS OF ASSOCIATIONS OF
RENAL PARAMETERS WITH METABOLIC AND
ANTHROPOMETRIC VARIABLES
Variable UAE
Serum
creatinine
Creatinine
clearance
Age –0.07 0.08 –0.26*
Duration of diabetes 0.07 0.12* –0.15*
BMI 0.00 0.12* 0.15*
WHR 0.04 0.39* 0.18*
eGDR –0.13* –0.17* 0.01
HbA1c 0.13* –0.08 –0.14*
Fasting glucose –0.02 0.02 –0.07
LDL cholesterol –0.00 0.04 –0.05
HDL cholesterol –0.04 –0.10 –0.09
Triglycerides 0.09 0.01 –0.14*
Systolic blood pressure 0.06 0.10 0.05
Diastolic blood pressure 0.06 0.08 0.08
*p<0.05, BMI – body mass index, WHR – waist to hip ratio,
eGDR – estimated glucose disposal rate, UAE – urinary albumin
excretion
TABLE 4
QUARTILES OF INSULIN RESISTANCE (EGDR)
Variable
1st quartile
eGDR<7.82
2nd quartile
7.82–9.67
3rd quartile
9.68–10.8
4th quartile
eGDR>10.8
p
for trend
Urinary albumin excretion (mg/24h) 16.4 (1–241) 15.8 (2–220) 14.5 (1–243) 12.6 (2–225) 0.01
Serum creatinine (mmol/L) 93.5±17.1 94.2±13.1 92.5±12.1 87.8±12.7 0.02
Creatinine clearance (ml/sec) 1.82±0.53 1.96±0.58 1.89±0.51 1.86±0.46 0.5
eGDR – estimated glucose disposal rate
ally important as a cardiovascular risk factor2,14. Previ-
ous studies in type 1 diabetes reported that patients with
lower insulin sensitivity have a higher subsequent risk of
developing the microvascular and macrovascular com-
plications4,10,15,26–29. Moreover, insulin resistance was fo-
und to be predominant predictor of overt nephropathy in
contrast to blood pressure and lipids in type 1 diabetes4.
In the present study we documented, among subjects
with type 1 diabetes, significant associations of renal pa-
rameters, including UAE and serum creatinine, with in-
sulin resistance measured by eGDR as well as with indi-
vidual components of insulin resistance. Furthermore,
we demonstrated that concentrations of UAE and serum
creatinine worsened in parallel with decreased in quar-
tiles of eGDR. A major change in insulin sensitivity had
already occurred in those with higher UAE and serum
creatinine before the decline in creatinine clearance as-
sociated with the late-stage disease. Furthermore, most
patients with microalbuminuria were in the lowest eGDR
quartile, thereby showing a clear relationship between
increased insulin resistance and microangiopathy. Fina-
lly, in logistic regression analysis only UAE was signifi-
cantly associated with the development of insulin resis-
tance in our subjects. Sample size, stable metabolic con-
trol (HbA1c 7.2 %), the relatively short duration of diabe-
tes (16 years) and satisfactory serum lipid concentrations
could probably explain the low prevalence of microalbu-
minuria in our study (17%). Moreover, frequency rates of
microalbuminuria in our study were similar to the overall
frequency in 1100 type 1 diabetic patients in the North
Wales Study (17%)30, and 15% in 4097 type 1 diabetic pa-
tients from National Diabetes Register in Sweden31.
There are few possible mechanisms to explain rela-
tionship between insulin resistance measured with eGDR
and worsening of renal function in type 1 diabetic pa-
tients. One of the main factors accounting for risk of pro-
gression to microalbuminuria is glycemic control32. Strict
blood glucose control reduces the risk of developing mi-
croalbuminuria and nephropathy in type 1 and 2 diabetic
patients18,20,33. This was also confirmed in our study were
HbA1c positively correlated with UAE, and negatively
with creatinine clearance. However, there is no glycemic
threshold for risk of microalbuminuria, and efforts to re-
duce HbA1c should therefore be continued at all le-
vels32,34. Apart from well-known risk factors such as
HbA1c, independent associations with microalbuminuria
were also observed with WHR. Moreover, EURODIAB
Prospective Complications Study (PCS) showed that ele-
vated WHR was risk factor for development of microalbu-
minuria, independently of diabetes duration and HbA1c32.
Higher WHR seems to indicate the existence of other
causative mechanisms than glycemic control only. Renal
damage by obesity may be also related to low-grade in-
flammation or to hormonal changes of the renin-angio-
tensin and sympathetic nervous system35. In our study
serum creatinine and creatinine clearance significantly
correlated with WHR, but this was not confirmed with
UAE. Data from previous cross-sectional studies showed
that lipids are abnormal in patients with higher UAE36,37.
However, lipids appear to predict risk of overt nephro-
pathy in type 1 diabetes only in the short term4. That
suggests that lipids mainly act as late-stage accelerators
or precipitators rather than underlying etiologic factor.
In our patients UAE and serum creatinine were not sig-
nificantly correlated with serum lipids.
Duration of diabetes has an impact on the risk of
microalbuminuria38. Most long-term epidemiologic stud-
ies have shown that 20 years duration of diabetes is a
time at which the annual incidence of new development
of microalbuminuria has already decreased markedly,
and those who do not have microalbuminuria by that
point are unlikely to ever develop it39,40. The mean dis-
ease duration of over 16 years in our study suggests that
our patients have a rather low risk of developing nephro-
pathy. The prospective studies also showed that elevated
blood pressure was an independent baseline risk factor
for the development of microalbuminuria21, although it
was not found to be either in the EURODIAB PCS on
1134 type 1 diabetic patients32, or in the study at Steno
Diabetes Center with over 400 type 1 diabetic patients41.
In our study systolic and diastolic blood pressure was not
significantly correlated with any renal parameter. How-
ever, impact of high blood pressure on renal function can
not be irrelevant, because blood pressure is one of the
component disorders of insulin resistance measured by
eGDR. In addition, it is known that strict blood pressure
control reduce UAE and deterioration of renal function
in type 1 diabetic patients21,41. Current smoking was sig-
nificantly associated with the risk of onset of microal-
buminuria42. In our study higher incident of smokers
were in group of patients with lower insulin sensitivity,
so it seems that current smoking and insulin sensitivity
may impact the risk of microalbuminuria through differ-
ent pathophysiological mechanisms.
In insulin resistant state, plasma insulin may rise to
supranormal concentrations that may sustain glomeru-
lar hyperfiltration43, endothelial dysfunction44, and in-
creased vascular permeability45, which can result in in-
creased UAE. Endothelium-dependent vasodilatation is
impaired in people with type 1 diabetes, especially in
those with higher UAE46. In addition, a link between
nephropathy and insulin resistance is consistent with
the Steno hypothesis that microalbuminuria reflects ge-
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TABLE 5
AGE ADJUSTED LOGISTIC REGRESSION ANALYSIS OF RENAL
PARAMETERS WITH DEVELOPMENT OF INSULIN RESISTANCE
IN TYPE 1 DIABETES
Independent
variable
Odds ratio p 95% Con. Int.
UAE 1.011 0.009 1.002–1.019
Serum
creatinine
1.006 0.412 0.991–1.021
Creatinine
clearance
0.977 0.924 0.617–1.549
UAE – urinary albumin excretion
neralized endothelial dysfunction47, which is known to
correlate with insulin resistance48. Moreover, impaired
insulin sensitivity is associated with altered renal cellu-
lar metabolism and electrolyte composition, mesangial
hyperplasia, renal hypertrophy and increased endothe-
lial cell proliferation, effects that may directly contribute
to progressive kidney damage49. Central actions of insu-
lin stimulating the sympathetic nervous system activity
and renal effects enhancing renal sodium reabsorption
may contribute to the etiology of arterial hypertension
that may further contribute to renal damage. Insulin re-
sistance might also contribute to nephropathy via low-
-grade inflammation and increased oxidative stress. It
was shown that increased concentrations of interleukin-
-6 and C-reactive protein are associated with decreased
insulin sensitivity, which worsened in parallel with the
severity of the renal disease6.
We did not have access to direct, detailed measures of
insulin resistance using euglycemic-hyperinsulinemic cla-
mp test, which can be potential limitation of this study. It
can be argued that, as eGDR is based on three risk fac-
tors, all we are doing is statistical manipulation. How-
ever, this computation is strongly related to measured
GDR (r=0.76)13, and those scoring high on eGDR clearly
have better insulin sensitivity and reduced risk for ne-
phropathy.
In summary, insulin resistance measured by eGDR
has a negative impact on renal parameters in type 1 dia-
betes, most notably UAE. Thus, an easy formula based
on clinical and laboratory parameters such as WHR,
blood pressure, and HbA1c, can provide a reliable assess-
ment of renal function as a chronic diabetes complica-
tion. Whether their total impact is greater than the sum
of the individual components is a matter of debate. The
close relationship between UAE and insulin resistance
has important implications for treatment. Microalbu-
minuria is one of several risk factors for end-stage renal
disease in diabetic patients and it is also an indicator of
organ dysfunction and a marker of greatly increased car-
diovascular morbidity and mortality in patients with
type 1 diabetes. Since progression to microalbuminuria
is likely to occur in majority of diabetic patients, there is
a need to further explore the role of risk factors such as
insulin resistance.
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UTJECAJ INZULINSKE REZISTENCIJE NA PARAMETRE BUBRE@NE FUNKCIJE U [E]ERNOJ
BOLESTI TIPA 1
S A @ E T A K
Pojam inzulinske rezistencije uglavnom se povezuje s razvojem {e}erne bolesti tipa 2, ali je pokazano da i osobe sa
{e}ernom bole{}u tipa 1 tako|er mogu imati zna~ajke inzulinske rezistencije. Inzulinska rezistencija u tipu 1 {e}erne
bolesti dokazano pridonosi razvoju mikro i makrovaskularnih komplikacija. Istra`ivali smo utjecaj inzulinske rezisten-
cije mjerene klini~kim parametrima na parametre bubre`ne funkcije: razinu albumina u urinu, serumski kreatinin i
klirens kreatinina. U istra`ivanje je uklju~eno 353 bolesnika sa {e}ernom bole{}u tipa 1, bez anamneze bubre`ne ili
kardiovaskularne bolesti. Inzulinska osjetljivost mjerena je eGDR-om (estimated glucose disposal rate) koji se ra~una
prema formuli: 24,31–(12,22´opseg struk/bokovi)–(3,29´povi{eni krvni tlak)–(0,57´HbA1c). Korelacijom i logisti~kom
regresijom analizirao se odnos izme|u parametara bubre`ne funkcije i eGDR-a, komponenti inzulinske rezistencije te s
rizikom razvoja inzulinske rezistencije. Razina albumina u urinu i serumski kreatinin zna~ajno su korelirali s eGDR-
-om (r=–0,13, i –0,17, p<0,05), kao i s pojedinim komponentama inzulinske rezistencije (opseg struk/bokovi, HbA1c).
Podijeliv{i razinu inzulinske osjetljivosti u kvartile, bolesnici u 1. kvartili eGDR-a imali su zna~ajno vi{e vrijednosti
albumina u urinu i serumskog kreatinina u odnosu na one u 4. kvartili. Logisti~kom regresijom dokazano je da samo
razina albumina u urinu utje~e na rizik razvoja inzulinske rezistencije (odds ratio=1,01, p<0,01). Rezultati istra`iva-
nja pokazali su da razina inzulinske osjetljivosti mjerena eGDR-om zna~ajno utje~e na parametre bubre`ne funkcije, i
to albumine u urinu i serumski kreatinin. Mikroalbuminurija je parametar pove}anog kardiovaskularnog rizika i smrt-
nosti, a budu}i da }e ve}ina bolesnika sa {e}ernom bole{}u tipa 1 tijekom vremena razviti mikroalbuminuriju, potrebno
je istra`iti ulogu faktora rizika kao {to je inzulinska rezistencija.
